George A Calin

List of Publications by Year in Descending Order

531 papers	91,284 citations	128 h-index	297 g-index
585 ext. papers	100,454 ext. citations	9.6 avg, IF	8.15 L-index

#	Paper	IF	Citations
531	RNAi-based therapeutics and tumor targeted delivery in cancer.. *Advanced Drug Delivery Reviews*, **2022**, 182, 114113	18.5	7
530	Analysis of the circRNA and T-UCR populations identifies convergent pathways in mouse and human models of Rett syndrome.. *Molecular Therapy - Nucleic Acids*, **2022**, 27, 621-644	10.7	1
529	microRNA in cancer: An overview **2022**, 21-28		0
528	Translational Modeling Identifies Synergy between Nanoparticle-Delivered miRNA-22 and Standard-of-Care Drugs in Triple-Negative Breast Cancer.. *Pharmaceutical Research*, **2022**, 39, 511	4.5	1
527	RNA delivery for cancer gene therapy **2022**, 375-424		
526	Serglycin Is Involved in TGF-Induced Epithelial-Mesenchymal Transition and Is Highly Expressed by Immune Cells in Breast Cancer Tissue.. *Frontiers in Oncology*, **2022**, 12, 868868	5.3	0
525	Targeting non-coding RNAs to overcome cancer therapy resistance.. *Signal Transduction and Targeted Therapy*, **2022**, 7, 121	21	4
524	lncRNAs UC.145 and PRKG1-AS1 Determine the Functional Output of DKK1 in Regulating the Wnt Signaling Pathway in Gastric Cancer. *Cancers*, **2022**, 14, 2369	6.6	
523	Dedifferentiation-mediated stem cell niche maintenance in early-stage ductal carcinoma in situ progression: insights from a multiscale modeling study. *Cell Death and Disease*, **2022**, 13,	9.8	1
522	Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth. *Cancer Research*, **2021**, 81, 501-514	10.1	5
521	APPLE and translation: When a small peptideproduced from a "non-coding RNA" matters!. *Molecular Cell*, **2021**, 81, 4349-4351	17.6	
520	Classical and noncanonical functions of miRNAs in cancers. *Trends in Genetics*, **2021**,	8.5	10
519	Quicker and digital: the way on protein biomarkers?. *Blood*, **2021**, 137, 1564-1565	2.2	
518	Being Small and Intronic: miRNAs That Count!. *Cancer Research*, **2021**, 81, 1212-1213	10.1	0
517	Effects of long non-coding RNAs on androgen signaling pathways in genitourinary malignancies. *Molecular and Cellular Endocrinology*, **2021**, 526, 111197	4.4	
516	TNF-alpha releasing capacity of the whole blood drops after open total splenectomy, but increases after partial/subtotal or minimally invasive splenectomy. *Acta Chirurgica Belgica*, **2021**, 1-11	0.9	
515	MicroRNA-138 suppresses glioblastoma proliferation through downregulation of CD44. *Scientific Reports*, **2021**, 11, 9219	4.9	5

514	Noncoding RNA therapeutics - challenges and potential solutions. *Nature Reviews Drug Discovery*, **2021**, 20, 629-651	64.1	140
513	Ultraconserved long non-coding RNA uc.112 is highly expressed in childhood T versus B-cell acute lymphoblastic leukemia. *Hematology, Transfusion and Cell Therapy*, **2021**, 43, 28-34	1.6	5
512	Cancer-Associated Neurogenesis and Nerve-Cancer Cross-talk. *Cancer Research*, **2021**, 81, 1431-1440	10.1	21
511	Editing and Chemical Modifications on Non-Coding RNAs in Cancer: A New Tale with Clinical Significance. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	13
510	Profiling Long Non-coding RNA expression Using Custom-Designed Microarray. *Methods in Molecular Biology*, **2021**, 2372, 43-51	1.4	
509	Non-coding RNAs regulation of macrophage polarization in cancer. *Molecular Cancer*, **2021**, 20, 24	42.1	19
508	Subcellular Localization of uc.8+ as a Prognostic Biomarker in Bladder Cancer Tissue. *Cancers*, **2021**, 13,	6.6	7
507	A noncoding RNA modulator potentiates phenylalanine metabolism in mice. *Science*, **2021**, 373, 662-673	33.3	9
506	Prognostic Value of Procalcitonin, C-Reactive Protein, and Lactate Levels in Emergency Evaluation of Cancer Patients with Suspected Infection. *Cancers*, **2021**, 13,	6.6	3
505	Immune Modulatory Short Noncoding RNAs Targeting the Glioblastoma Microenvironment. *Frontiers in Oncology*, **2021**, 11, 682129	5.3	2
504	CRISPR/Cas9 to Silence Long Non-Coding RNAs. *Methods in Molecular Biology*, **2021**, 2348, 175-187	1.4	3
503	A mathematical model for the quantification of a patientIs sensitivity to checkpoint inhibitors and long-term tumour burden. *Nature Biomedical Engineering*, **2021**, 5, 297-308	19	12
502	A Holistic Perspective: Exosomes Shuttle between Nerves and Immune Cells in the Tumor Microenvironment. *Journal of Clinical Medicine*, **2020**, 9,	5.1	8
501	Classic and targeted anti-leukaemic agents interfere with the cholesterol biogenesis metagene in acute myeloid leukaemia: Therapeutic implications. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 7378-7392	5.6	8
500	The Interplay between MicroRNAs and the Components of the Tumor Microenvironment in B-Cell Malignancies. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	9
499	How Does a Tumor Get Its Shape? MicroRNAs Act as Morphogens at the Cancer Invasion Front. *Non-coding RNA*, **2020**, 6,	7.1	2
498	A New World of Biomarkers and Therapeutics for Female Reproductive System and Breast Cancers: Circular RNAs. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 50	5.7	28
497	Non-coding RNAs in GI cancers: from cancer hallmarks to clinical utility. *Gut*, **2020**, 69, 748-763	19.2	74

496	Frequent methylation of the tumour suppressor miR-1258 targeting PDL1: implication in multiple myeloma-specific cytotoxicity and prognostification. *British Journal of Haematology*, **2020**, 190, 249-261	4.5	6
495	Loss of p53 drives neuron reprogramming in head and neck cancer. *Nature*, **2020**, 578, 449-454	50.4	99
494	Long non-coding RNA uc.291 controls epithelial differentiation by interfering with the ACTL6A/BAF complex. *EMBO Reports*, **2020**, 21, e46734	6.5	11
493	Therapeutic potential of FLANC, a novel primate-specific long non-coding RNA in colorectal cancer. *Gut*, **2020**, 69, 1818-1831	19.2	49
492	RNA-Binding Proteins as Important Regulators of Long Non-Coding RNAs in Cancer. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	41
491	miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2. *JCI Insight*, **2020**, 5,	9.9	13
490	Tumorigenesis-Related Long Noncoding RNAs and Their Targeting as Therapeutic Approach in Cancer. *RNA Technologies*, **2020**, 277-303	0.2	
489	Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. *Cancer Drug Resistance (Alhambra, Calif)*, **2020**, 3, 356-370	4.5	9
488	Pseudogenes, RNAs and new reproducibility norms. *ELife*, **2020**, 9,	8.9	1
487	Diagnostic and Therapeutic MicroRNAs in Primary Myelofibrosis. *Proceedings of the Singapore National Academy of Science*, **2020**, 14, 91-109	0.1	
486	A Multiscale Agent-Based Model of Ductal Carcinoma In Situ. *IEEE Transactions on Biomedical Engineering*, **2020**, 67, 1450-1461	5	8
485	Highlighting transcribed ultraconserved regions in human diseases. *Wiley Interdisciplinary Reviews RNA*, **2020**, 11, e1567	9.3	11
484	GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma. *Cellular Signalling*, **2020**, 68, 109539	4.9	32
483	Therapeutic Potential of the miRNA-ATM Axis in the Management of Tumor Radioresistance. *Cancer Research*, **2020**, 80, 139-150	10.1	13
482	Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum. *RNA Biology*, **2020**, 17, 1523-1534	4.8	9
481	Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 828	5.7	15
480	FuncPEP: A Database of Functional Peptides Encoded by Non-Coding RNAs. *Non-coding RNA*, **2020**, 6,	7.1	10
479	Epigenetic silencing of miR-342-3p in B cell lymphoma and its impact on autophagy. *Clinical Epigenetics*, **2020**, 12, 150	7.7	4

478	Neural reprogramming via microRNAs: the new kid on the p53-deficient block. *Molecular and Cellular Oncology*, **2020**, 7, 1756723	1.2	
477	Pyknon-Containing Transcripts Are Downregulated in Colorectal Cancer Tumors, and Loss of Is Associated With Worse Patient Outcome. *Frontiers in Genetics*, **2020**, 11, 581454	4.5	2
476	lncRNA and Mechanisms of Drug Resistance in Cancers of the Genitourinary System. *Cancers*, **2020**, 12,	6.6	16
475	MicroRNAs from Liquid Biopsy Derived Extracellular Vesicles: Recent Advances in Detection and Characterization Methods. *Cancers*, **2020**, 12,	6.6	21
474	Epigenetic deregulation in cancer: Enzyme players and non-coding RNAs. *Seminars in Cancer Biology* , **2020**,	12.7	6
473	The Long Noncoding RNA CCAT2 Induces Chromosomal Instability Through BOP1-AURKB Signaling. *Gastroenterology*, **2020**, 159, 2146-2162.e33	13.3	34
472	When non-coding is not enough. *Journal of Experimental Medicine*, **2020**, 217,	16.6	4
471	Non-Coding RNAs as Cancer Hallmarks in Chronic Lymphocytic Leukemia. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	2
470	Epigenetic silencing of long non-coding RNA in multiple myeloma: impact on prognosis and myeloma dissemination. *Cancer Cell International*, **2020**, 20, 403	6.4	7
469	Interrupting Neuron-Tumor Interactions to Overcome Treatment Resistance. *Cancers*, **2020**, 12,	6.6	1
468	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. *Gut*, **2020**, 69, 18-31	19.2	39
467	Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer. *Journal of the National Cancer Institute*, **2020**, 112, 266-277	9.7	3
466	GLS2 is protumorigenic in breast cancers. *Oncogene*, **2020**, 39, 690-702	9.2	15
465	The non-coding RNome after splenectomy. *Journal of Cellular and Molecular Medicine*, **2019**, 23, 7844-7858	5.3	11
464	Decrypting noncoding RNA interactions, structures, and functional networks. *Genome Research*, **2019**, 29, 1377-1388	9.7	57
463	MiR-200 family and cancer: From a meta-analysis view. *Molecular Aspects of Medicine*, **2019**, 70, 57-71	16.7	30
462	Long Non-coding RNAs in Myeloid Malignancies. *Frontiers in Oncology*, **2019**, 9, 1048	5.3	21
461	The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database. *Journal of Translational Medicine*, **2019**, 17, 318	8.5	10

460	Current concepts of non-coding RNA regulation of immune checkpoints in cancer. *Molecular Aspects of Medicine*, **2019**, 70, 117-126	16.7	32
459	New Insights into the Molecular Mechanisms of Long Non-coding RNAs in Cancer Biology **2019**, 85-113		
458	The Interaction Between Two Worlds: MicroRNAs and Toll-Like Receptors. *Frontiers in Immunology*, **2019**, 10, 1053	8.4	59
457	MicroRNA based theranostics for brain cancer: basic principles. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 231	12.8	53
456	Epigenetic silencing of miR-340-5p in multiple myeloma: mechanisms and prognostic impact. *Clinical Epigenetics*, **2019**, 11, 71	7.7	16
455	MicroRNAs and Long Non-Coding RNAs and Their Hormone-Like Activities in Cancer. *Cancers*, **2019**, 11,	6.6	25
454	Mir-roring hypoxia in EGFR-TKI tolerance. *Nature Metabolism*, **2019**, 1, 418-419	14.6	2
453	The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research. *Cell*, **2019**, 177, 231-242	56.2	91
452	Interplay between epigenetic abnormalities and deregulated expression of microRNAs in cancer. *Seminars in Cancer Biology*, **2019**, 58, 47-55	12.7	20
451	MicroRNA in lung cancer: role, mechanisms, pathways and therapeutic relevance. *Molecular Aspects of Medicine*, **2019**, 70, 3-20	16.7	180
450	Current Concepts of Non-Coding RNAs in the Pathogenesis of Non-Clear Cell Renal Cell Carcinoma. *Cancers*, **2019**, 11,	6.6	24
449	Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey. *Cells*, **2019**, 8,	7.9	13
448	Genetic Variations of Ultraconserved Elements in the Human Genome. *OMICS A Journal of Integrative Biology*, **2019**, 23, 549-559	3.8	6
447	The role of exosomal long non-coding RNAs in cancer drug resistance. *Cancer Drug Resistance (Alhambra, Calif)*, **2019**, 2, 1178-1192	4.5	17
446	Non-Coding RNAs in IGF-1R Signaling Regulation: The Underlying Pathophysiological Link between Diabetes and Cancer. *Cells*, **2019**, 8,	7.9	27
445	Role of miRNAs in immune responses and immunotherapy in cancer. *Genes Chromosomes and Cancer*, **2019**, 58, 244-253	5	63
444	miRNA Expression Assays **2019**, 51-71		1
443	The involvement of microRNA in the pathogenesis of Richter syndrome. *Haematologica*, **2019**, 104, 100461015		14

442	The Modulatory Role of MicroRNA-873 in the Progression of KRAS-Driven Cancers. *Molecular Therapy - Nucleic Acids*, **2019**, 14, 301-317	10.7	17
441	Circulating inflammation signature predicts overall survival and relapse-free survival in metastatic colorectal cancer. *British Journal of Cancer*, **2019**, 120, 340-345	8.7	17
440	Measurement of miRNAs in Chronic Lymphocytic Leukemia Patient Samples by Quantitative Reverse Transcription PCR. *Methods in Molecular Biology*, **2019**, 1881, 267-276	1.4	1
439	miR-181a/b therapy in lung cancer: reality or myth?. *Molecular Oncology*, **2019**, 13, 9-25	7.9	21
438	Preface for GCC Special Issue on noncoding RNAs, noncoding DNAs, and genome editing. *Genes Chromosomes and Cancer*, **2019**, 58, 189-190	5	1
437	S-MiRAGE: A Quantitative, Secreted RNA-Based Reporter of Gene Expression and Cell Persistence. *ACS Synthetic Biology*, **2019**, 8, 25-33	5.7	
436	Long non-coding RNAs within the tumour microenvironment and their role in tumour-stroma cross-talk. *Cancer Letters*, **2018**, 421, 94-102	9.9	18
435	Hematopoietic stem cells from induced pluripotent stem cells - considering the role of microRNA as a cell differentiation regulator. *Journal of Cell Science*, **2018**, 131,	5.3	19
434	A-to-I miR-378a-3p editing can prevent melanoma progression via regulation of PARVA expression. *Nature Communications*, **2018**, 9, 461	17.4	39
433	MiR-181 family-specific behavior in different cancers: a meta-analysis view. *Cancer and Metastasis Reviews*, **2018**, 37, 17-32	9.6	35
432	Featuring the special issue Guest Editor. *Cancer Letters*, **2018**, 423, 27	9.9	
431	Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA induce myeloid malignancies via unique SNP-specific RNA mutations. *Genome Research*, **2018**, 28, 432-447	9.7	45
430	Germline polymorphisms in myeloid-associated genes are not associated with survival in glioma patients. *Journal of Neuro-Oncology*, **2018**, 136, 33-39	4.8	2
429	Serum HOTAIR and GAS5 levels as predictors of survival in patients with glioblastoma. *Molecular Carcinogenesis*, **2018**, 57, 137-141	5	53
428	Association Between Germline Mutations in BRF1, a Subunit of the RNA Polymerase III Transcription Complex, and Hereditary Colorectal Cancer. *Gastroenterology*, **2018**, 154, 181-194.e20	13.3	25
427	Circular RNAs in Cancer - Lessons Learned From microRNAs. *Frontiers in Oncology*, **2018**, 8, 179	5.3	72
426	Using microRNA Networks to Understand Cancer. *International Journal of Molecular Sciences*, **2018**, 19,	6.3	52
425	Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. *Haematologica*, **2018**, 103, 2069-2078	6.6	13

424	Trastuzumab upregulates PD-L1 as a potential mechanism of trastuzumab resistance through engagement of immune effector cells and stimulation of IFN secretion. *Cancer Letters*, **2018**, 430, 47-56	9.9	57
423	MicroRNAs, Regulatory Messengers Inside and Outside Cancer Cells. *Advances in Experimental Medicine and Biology*, **2018**, 1056, 87-108	3.6	48
422	Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. *Clinical Cancer Research*, **2018**, 24, 4225-4241	12.9	48
421	Profiling the circulating miRnome reveals a temporal regulation of the bone injury response. *Theranostics*, **2018**, 8, 3902-3917	12.1	8
420	MYC-related microRNAs signatures in non-Hodgkin B-cell lymphomas and their relationships with core cellular pathways. *Oncotarget*, **2018**, 9, 29753-29771	3.3	9
419	New Definitions of Sepsis and the Quest for Specific Biomarkers. Are the miRNAs the Answer?. *Chirurgia (Romania)*, **2018**, 113, 464-468	1.8	3
418	Tyrosine Kinases, microRNAs, Epigenetics: New Insights in the Mechanisms of Leukemogenesis **2018**, 11-25		
417	Roles and clinical implications of microRNAs in acute lymphoblastic leukemia. *Journal of Cellular Physiology*, **2018**, 233, 5642-5654	7	28
416	The Many Faces of Long Noncoding RNAs in Cancer. *Antioxidants and Redox Signaling*, **2018**, 29, 922-935	8.4	27
415	Exosomal lncRNAs as new players in cell-to-cell communication. *Translational Cancer Research*, **2018** , 7, S243-S252	0.3	97
414	Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. *EBioMedicine*, **2018**, 38, 100-112	8.8	100
413	Key questions about the checkpoint blockade-are microRNAs an answer?. *Cancer Biology and Medicine*, **2018**, 15, 103-115	5.2	29
412	miR-122 and hepatocellular carcinoma: from molecular biology to therapeutics. *EBioMedicine*, **2018**, 37, 17-18	8.8	13
411	Metformin blocks MYC protein synthesis in colorectal cancer via mTOR-4EBP-eIF4E and MNK1-eIF4G-eIF4E signaling. *Molecular Oncology*, **2018**, 12, 1856-1870	7.9	17
410	OncomiR-10b hijacks the small molecule inhibitor linifanib in human cancers. *Scientific Reports*, **2018**, 8, 13106	4.9	12
409	Clinical utility of circulating non-coding RNAs - an update. *Nature Reviews Clinical Oncology*, **2018**, 15, 541-563	19.4	230
408	Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. *Breast Cancer Research and Treatment*, **2018**, 171, 593-605	4.4	43
407	Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics. *FEBS Journal* , **2017**, 284, 1952-1966	5.7	82

406	MALAT1 promoted invasiveness of gastric adenocarcinoma. *BMC Cancer*, **2017**, 17, 46	4.8	43
405	HIF1A gene polymorphisms and human diseases: Graphical review of 97 association studies. *Genes Chromosomes and Cancer*, **2017**, 56, 439-452	5	20
404	Plasma Viral miRNAs Indicate a High Prevalence of Occult Viral Infections. *EBioMedicine*, **2017**, 20, 182-192	8	15
403	Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers. *Clinical Cancer Research*, **2017**, 23, 2891-2904	12.9	90
402	MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. *Oncogene*, **2017**, 36, 2667-2679	9.2	27
401	Dendritic Cell-derived Extracellular Vesicles mediate Mesenchymal Stem/Stromal Cell recruitment. *Scientific Reports*, **2017**, 7, 1667	4.9	41
400	N-BLR, a primate-specific non-coding transcript leads to colorectal cancer invasion and migration. *Genome Biology*, **2017**, 18, 98	18.3	75
399	miR-196b-5p Regulates Colorectal Cancer Cell Migration and Metastases through Interaction with HOXB7 and GALNT5. *Clinical Cancer Research*, **2017**, 23, 5255-5266	12.9	60
398	Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes. *Oncogene*, **2017**, 36, 5734-5744	9.2	21
397	Regulation of PI3K signaling in T-cell acute lymphoblastic leukemia: a novel PTEN/Ikaros/miR-26b mechanism reveals a critical targetable role for PIK3CD. *Leukemia*, **2017**, 31, 2355-2364	10.7	36
396	Non-coding RNAs: the cancer genome dark matter that matters!. *Clinical Chemistry and Laboratory Medicine*, **2017**, 55, 705-714	5.9	42
395	The emerging role of long noncoding RNAs in oral cancer. *Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology*, **2017**, 123, 235-241	2	39
394	A total transcriptome profiling method for plasma-derived extracellular vesicles: applications for liquid biopsies. *Scientific Reports*, **2017**, 7, 14395	4.9	44
393	Cell-to-cell communication: microRNAs as hormones. *Molecular Oncology*, **2017**, 11, 1673-1686	7.9	186
392	TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p. *Nature Communications*, **2017**, 8, 947	17.4	26
391	Understanding the Genomic Ultraconservations: T-UCRs and Cancer. *International Review of Cell and Molecular Biology*, **2017**, 333, 159-172	6	21
390	miR-195 inhibits macrophages pro-inflammatory profile and impacts the crosstalk with smooth muscle cells. *PLoS ONE*, **2017**, 12, e0188530	3.7	32
389	Cancer Hallmarks and MicroRNAs: The Therapeutic Connection. *Advances in Cancer Research*, **2017**, 135, 119-149	5.9	96

388	Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. *Oncotarget*, **2017**, 8, 20145-20164	3.3	43
387	MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. *Oncotarget*, **2017**, 8, 11641-11658	3.3	59
386	Exosomes from Glioma-Associated Mesenchymal Stem Cells Increase the Tumorigenicity of Glioma Stem-like Cells via Transfer of miR-1587. *Cancer Research*, **2017**, 77, 5808-5819	10.1	126
385	The role of a new class of long noncoding RNAs transcribed from ultraconserved regions in cancer. *Biochimica Et Biophysica Acta: Reviews on Cancer*, **2017**, 1868, 449-455	11.2	29
384	Regulation of hnRNPA1 by microRNAs controls the miR-18a- axis in chemotherapy-resistant ovarian cancer. *Cell Discovery*, **2017**, 3, 17029	22.3	20
383	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. *Oncogene*, **2017**, 36, 6617-6626	9.2	16
382	microRNA Expression in Ethnic Specific Early Stage Breast Cancer: an Integration and Comparative Analysis. *Scientific Reports*, **2017**, 7, 16829	4.9	15
381	Transcribed ultraconserved region 339 promotes carcinogenesis by modulating tumor suppressor microRNAs. *Nature Communications*, **2017**, 8, 1801	17.4	28
380	CCAT1 and CCAT2 long noncoding RNAs, located within the 8q.24.21 'gene desert', serve as important prognostic biomarkers in colorectal cancer. *Annals of Oncology*, **2017**, 28, 1882-1888	10.3	113
379	Genome-Wide miRNA Analysis Identifies miR-188-3p as a Novel Prognostic Marker and Molecular Factor Involved in Colorectal Carcinogenesis. *Clinical Cancer Research*, **2017**, 23, 1323-1333	12.9	55
378	Ultraconserved long non-coding RNA uc.63 in breast cancer. *Oncotarget*, **2017**, 8, 35669-35680	3.3	27
377	To Wnt or Lose: The Missing Non-Coding Linc in Colorectal Cancer. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	40
376	Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	15
375	Current Insights into Long Non-Coding RNAs (LncRNAs) in Prostate Cancer. *International Journal of Molecular Sciences*, **2017**, 18,	6.3	53
374	MicroRNAs: Clinical Trials and Potential Applications?. *Clinical Journal of Oncology Nursing*, **2017**, 21, 554-559	1.5	8
373	Circulating miRNAs in sepsis-A network under attack: An in-silico prediction of the potential existence of miRNA sponges in sepsis. *PLoS ONE*, **2017**, 12, e0183334	3.7	25
372	PD-L1 expression and prognostic impact in glioblastoma. *Neuro-Oncology*, **2016**, 18, 195-205	1	331
371	The clinical and biological significance of MIR-224 expression in colorectal cancer metastasis. *Gut*, **2016**, 65, 977-989	19.2	99

370	From cell biology to immunology: Controlling metastatic progression of cancer via microRNA regulatory networks. *OncoImmunology*, **2016**, 5, e1230579	7.2	4
369	Cellular and viral microRNAs in sepsis: mechanisms of action and clinical applications. *Cell Death and Differentiation*, **2016**, 23, 1906-1918	12.7	33
368	Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. *Cancer Research*, **2016**, 76, 7194-7207	10.1	92
367	The Potential of MicroRNAs as Prostate Cancer Biomarkers. *European Urology*, **2016**, 70, 312-22	10.2	169
366	Soy Isoflavone Genistein-Mediated Downregulation of miR-155 Contributes to the Anticancer Effects of Genistein. *Nutrition and Cancer*, **2016**, 68, 154-64	2.8	72
365	MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. *Neuro-Oncology*, **2016**, 18, 639-48	11	124
364	MicroRNAs in chronic lymphocytic leukemia: miRacle or miRage for prognosis and targeted therapies?. *Seminars in Oncology*, **2016**, 43, 209-14	5.5	23
363	miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. *Cancer Discovery*, **2016**, 6, 235-46	24.4	404
362	Allele-Specific Reprogramming of Cancer Metabolism by the Long Non-coding RNA CCAT2. *Molecular Cell*, **2016**, 61, 520-534	17.6	101
361	Circulating free xeno-microRNAs - The new kids on the block. *Molecular Oncology*, **2016**, 10, 503-8	7.9	36
360	Hypoxia-upregulated microRNA-630 targets Dicer, leading to increased tumor progression. *Oncogene*, **2016**, 35, 4312-20	9.2	70
359	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. *Clinical Cancer Research*, **2016**, 22, 2359-67	12.9	22
358	PDL1 Regulation by p53 via miR-34. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	351
357	Globally increased ultraconserved noncoding RNA expression in pancreatic adenocarcinoma. *Oncotarget*, **2016**, 7, 53165-53177	3.3	27
356	MiR-223-5p works as an oncomiR in vulvar carcinoma by TP63 suppression. *Oncotarget*, **2016**, 7, 49217-49231	3.3	21
355	miR-195 in human primary mesenchymal stromal/stem cells regulates proliferation, osteogenesis and paracrine effect on angiogenesis. *Oncotarget*, **2016**, 7, 7-22	3.3	61
354	Examining plasma microRNA markers for colorectal cancer at different stages. *Oncotarget*, **2016**, 7, 11434-49	3.3	63
353	Therapeutic evaluation of microRNA-15a and microRNA-16 in ovarian cancer. *Oncotarget*, **2016**, 7, 15093-104	3.3	49

352	Long non-coding RNA containing ultraconserved genomic region 8 promotes bladder cancer tumorigenesis. *Oncotarget*, **2016**, 7, 20636-54	3.3	56
351	Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. *Oncotarget*, **2016**, 7, 31361-71	3.3	33
350	Patients After Splenectomy: Old Risks and New Perspectives. *Chirurgia (Romania)*, **2016**, 111, 393-399	1.8	13
349	MicroRNAs in Chronic Lymphocytic Leukemia: An Old Disease with New Genetic Insights. *MicroRNA (Shariqah, United Arab Emirates)*, **2016**, 5, 106-112	2.9	2
348	Profiling Long Noncoding RNA Expression Using Custom-Designed Microarray. *Methods in Molecular Biology*, **2016**, 1402, 33-41	1.4	5
347	Current Status of Long Non-Coding RNAs in Human Breast Cancer. *International Journal of Molecular Sciences*, **2016**, 17,	6.3	55
346	Bigger Data Is Better for Molecular Diagnosis Tests Based on Decision Trees. *Lecture Notes in Computer Science*, **2016**, 288-295	0.9	1
345	Targeting microRNAs as key modulators of tumor immune response. *Journal of Experimental and Clinical Cancer Research*, **2016**, 35, 103	12.8	118
344	Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases. *Genes Chromosomes and Cancer*, **2016**, 55, 193-214	5	50
343	H19 Noncoding RNA, an Independent Prognostic Factor, Regulates Essential Rb-E2F and CDK8-Catenin Signaling in Colorectal Cancer. *EBioMedicine*, **2016**, 13, 113-124	8.8	84
342	The interplay between lnRNAs, SNPs, and protein complexes - what does it mean for cancer metabolism?. *Molecular and Cellular Oncology*, **2016**, 3, e1166308	1.2	1
341	Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. *OncoImmunology*, **2016**, 5, e1117739	7.2	6
340	Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. *Oncogene*, **2016**, 35, 4914-26	9.2	41
339	miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. *Journal of the National Cancer Institute*, **2016**, 108,	9.7	52
338	Direct Upregulation of STAT3 by MicroRNA-551b-3p Deregulates Growth and Metastasis of Ovarian Cancer. *Cell Reports*, **2016**, 15, 1493-1504	10.6	56
337	When kissing (disease) counts. *Blood*, **2016**, 127, 1947-8	2.2	3
336	microRNA Therapeutics in Cancer - An Emerging Concept. *EBioMedicine*, **2016**, 12, 34-42	8.8	275
335	From mobility to crosstalk. A model of intracellular miRNAs motion may explain the RNAs interaction mechanism on the basis of target subcellular localization. *Mathematical Biosciences*, **2016**, 280, 50-61	3.9	12

334	Hodgkin Lymphoma Cells Have a Specific Long Noncoding RNA Expression Pattern. *American Journal of Pathology*, **2016**, 186, 2251-3	5.8	1
333	A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients. *Clinical Cancer Research*, **2015**, 21, 1207-14	12.9	156
332	Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. *Clinical Cancer Research*, **2015**, 21, 2127-37	12.9	49
331	DrugMicroRNA Cross-Talk **2015**, 991-1016		1
330	PRUNE2 is a human prostate cancer suppressor regulated by the intronic long noncoding RNA PCA3. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 8403-8	11.5	179
329	The ZNF304-integrin axis protects against anoikis in cancer. *Nature Communications*, **2015**, 6, 7351	17.4	37
328	MicroRNAs in cancer: from developmental genes in worms to their clinical application in patients. *British Journal of Cancer*, **2015**, 113, 569-73	8.7	163
327	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, E1106-15	11.5	307
326	Exosome-mediated transfer of microRNAs within the tumor microenvironment and neuroblastoma resistance to chemotherapy. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	232
325	MiRNA Expression Assays **2015**, 45-70		
324	Synchronous down-modulation of miR-17 family members is an early causative event in the retinal angiogenic switch. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 3770-5	11.5	30
323	Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens. *Clinical Cancer Research*, **2015**, 21, 3041-51	12.9	8
322	Data Normalization Strategies for MicroRNA Quantification. *Clinical Chemistry*, **2015**, 61, 1333-42	5.5	287
321	MicroRNA Involvement in Intestinal Tumorigenesis **2015**, 169-188		
320	The role of p19 and p21 H-Ras proteins and mutants in miRNA expression in cancer and a Costello syndrome cell model. *BMC Medical Genetics*, **2015**, 16, 46	2.1	6
319	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. *EBioMedicine*, **2015**, 2, 572-82	8.8	34
318	Design of a miRNA sponge for the miR-17 miRNA family as a therapeutic strategy against vulvar carcinoma. *Molecular and Cellular Probes*, **2015**, 29, 420-426	3.3	15
317	Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. *Oncogene*, **2015**, 34, 1619-1628	9.2	66

316	Clinically relevant microRNAs in ovarian cancer. *Molecular Cancer Research*, **2015**, 13, 393-401	6.6	75
315	Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes. *Modern Pathology*, **2015**, 28, 373-82	9.8	26
314	Small molecule compounds targeting miRNAs for cancer therapy. *Advanced Drug Delivery Reviews*, **2015**, 81, 104-16	18.5	111
313	Long non-coding RNAs in primary myelofibrosis: the dark matter in hematopoietic progenitor cells?. *Leukemia and Lymphoma*, **2015**, 56, 281-2	1.9	
312	Exosomes as divine messengers: are they the Hermes of modern molecular oncology?. *Cell Death and Differentiation*, **2015**, 22, 34-45	12.7	205
311	Therapeutic Potential of microRNAs **2015**, 543-564		
310	IMPS-28PD-L1 EXPRESSION AND PROGNOSTIC IMPACT IN GLIOBLASTOMA. *Neuro-Oncology*, **2015**, 17, v119.2-v119	1	3
309	Tracking miRNAsLfootprints in tumor-microenvironment interactions: Insights and implications for targeted cancer therapy. *Genes Chromosomes and Cancer*, **2015**, 54, 335-52	5	12
308	MicroRNA Processing and Human Cancer. *Journal of Clinical Medicine*, **2015**, 4, 1651-67	5.1	126
307	Inflamma-miRs in Aging and Breast Cancer: Are They Reliable Players?. *Frontiers in Medicine*, **2015**, 2, 85	4.9	21
306	Progresses towards safe and efficient gene therapy vectors. *Oncotarget*, **2015**, 6, 30675-703	3.3	136
305	The Clinical Relevance of Long Non-Coding RNAs in Cancer. *Cancers*, **2015**, 7, 2169-82	6.6	98
304	An updated h-index measures both the primary and total scientific output of a researcher. *Discoveries*, **2015**, 3,	3.7	9
303	Exosomal Non-Coding RNAs: Diagnostic, Prognostic and Therapeutic Applications in Cancer. *Non-coding RNA*, **2015**, 1, 53-68	7.1	57
302	VEGFR-1 Pseudogene Expression and Regulatory Function in Human Colorectal Cancer Cells. *Molecular Cancer Research*, **2015**, 13, 1274-82	6.6	17
301	From the Biology of PP2A to the PADs for Therapy of Hematologic Malignancies. *Frontiers in Oncology*, **2015**, 5, 21	5.3	32
300	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. *Molecular Therapy - Nucleic Acids*, **2015**, 4, e270	10.7	47
299	Long Noncoding RNA Ceruloplasmin Promotes Cancer Growth by Altering Glycolysis. *Cell Reports*, **2015**, 13, 2395-2402	10.6	75

298	The fusion of two worlds: non-coding RNAs and extracellular vesicles--diagnostic and therapeutic implications (Review). *International Journal of Oncology*, **2015**, 46, 17-27	4.4	152
297	microRNA and Chronic Lymphocytic Leukemia. *Advances in Experimental Medicine and Biology*, **2015**, 889, 23-40	3.6	10
296	Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. *Nature Cell Biology*, **2015**, 17, 311-21	23.4	155
295	Junk DNA and the long non-coding RNA twist in cancer genetics. *Oncogene*, **2015**, 34, 5003-11	9.2	231
294	An Integrative Analysis to Identify Driver Genes in Esophageal Squamous Cell Carcinoma. *PLoS ONE*, **2015**, 10, e0139808	3.7	13
293	Stratifying risk of recurrence in stage II colorectal cancer using deregulated stromal and epithelial microRNAs. *Oncotarget*, **2015**, 6, 7262-79	3.3	33
292	Low spinophilin expression enhances aggressive biological behavior of breast cancer. *Oncotarget*, **2015**, 6, 11191-202	3.3	9
291	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. *Oncotarget*, **2015**, 6, 37269-80	3.3	112
290	MicroRNAs in Myeloid Hematological Malignancies. *Current Genomics*, **2015**, 16, 336-48	2.6	5
289	MicroRNAs as Therapeutic Targets **2015**, 683-697		1
288	ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance. *Blood Cells, Molecules, and Diseases*, **2014**, 53, 47-55	2.1	24
287	Long noncoding RNA in prostate, bladder, and kidney cancer. *European Urology*, **2014**, 65, 1140-51	10.2	471
286	The Role of MicroRNAs and Ultraconserved Non-Coding RNAs in Cancer **2014**, 435-447		2
285	Clinical relevance of circulating cell-free microRNAs in cancer. *Nature Reviews Clinical Oncology*, **2014**, 11, 145-56	19.4	740
284	Circulating microRNAs as Promising Tumor Biomarkers. *Advances in Clinical Chemistry*, **2014**, 67, 189-214	5.8	28
283	Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. *Nature Communications*, **2014**, 5, 5202	17.4	130
282	Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. *Cancer Cell*, **2014**, 26, 707-21	24.3	1032
281	SnapShot: chronic lymphocytic leukemia. *Cancer Cell*, **2014**, 26, 770-770.e1	24.3	7

280	MicroRNAome genome: a treasure for cancer diagnosis and therapy. *Ca-A Cancer Journal for Clinicians*, **2014**, 64, 311-36	220.7	354
279	The decalog of long non-coding RNA involvement in cancer diagnosis and monitoring. *Critical Reviews in Clinical Laboratory Sciences*, **2014**, 51, 344-57	9.4	76
278	Targeting the microRNA-regulating DNA damage/repair pathways in cancer. *Expert Opinion on Biological Therapy*, **2014**, 14, 1667-83	5.4	34
277	Effect of miR-142-3p on the M2 macrophage and therapeutic efficacy against murine glioblastoma. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	80
276	MicroRNAs as therapeutic targets in human cancers. *Wiley Interdisciplinary Reviews RNA*, **2014**, 5, 537-48	9.3	60
275	miR-203 induces oxaliplatin resistance in colorectal cancer cells by negatively regulating ATM kinase. *Molecular Oncology*, **2014**, 8, 83-92	7.9	133
274	HypoxamiRs and cancer: from biology to targeted therapy. *Antioxidants and Redox Signaling*, **2014**, 21, 1220-38	8.4	74
273	microRNAome expression in chronic lymphocytic leukemia: comparison with normal B-cell subsets and correlations with prognostic and clinical parameters. *Clinical Cancer Research*, **2014**, 20, 4141-53	12.9	41
272	MicroRNAs and ceRNAs: therapeutic implications of RNA networks. *Expert Opinion on Biological Therapy*, **2014**, 14, 1285-93	5.4	42
271	Regulation of pri-miRNA processing by a long noncoding RNA transcribed from an ultraconserved region. *Molecular Cell*, **2014**, 55, 138-47	17.6	111
270	The protein phosphatase 2A regulatory subunit B55 is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. *Biochimica Et Biophysica Acta - Molecular Cell Research*, **2014**, 1843, 1969-77	4.9	27
269	MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia. *Blood*, **2014**, 124, 546-54	2.2	127
268	High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. *PLoS ONE*, **2014**, 9, e83113	3.7	65
267	Key principles of miRNA involvement in human diseases. *Discoveries*, **2014**, 2, e34	3.7	38
266	MicroRNAs as main players in the pathogenesis of chronic lymphocytic leukemia. *MicroRNA (Shariqah, United Arab Emirates)*, **2014**, 2, 158-64	2.9	16
265	A large scale expression study associates uc.283-plus lncRNA with pluripotent stem cells and human glioma. *Genome Medicine*, **2014**, 6, 76	14.4	29
264	RNAi therapies: drugging the undruggable. *Science Translational Medicine*, **2014**, 6, 240ps7	17.5	176
263	Epigenetically regulated microRNAs and their prospect in cancer diagnosis. *Expert Review of Molecular Diagnostics*, **2014**, 14, 673-83	3.8	14

262	Cellular and Kaposiɪs sarcoma-associated herpes virus microRNAs in sepsis and surgical trauma. *Cell Death and Disease*, **2014**, 5, e1559	9.8	30
261	In situ hybridization-based detection of microRNAs in human diseases **2014**, 1,		1
260	Molecular pathways: microRNAs, cancer cells, and microenvironment. *Clinical Cancer Research*, **2014** , 20, 6247-53	12.9	83
259	MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients. *British Journal of Cancer*, **2014**, 110, 1614-21	8.7	92
258	FOXP3 is a direct target of miR15a/16 in umbilical cord blood regulatory T cells. *Bone Marrow Transplantation*, **2014**, 49, 793-9	4.4	28
257	Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. *Molecular Therapy*, **2014**, 22, 1494-1503	11.7	142
256	The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. *Nucleic Acids Research*, **2014**, 42, e133	20.1	192
255	Clinical significance of the interaction between non-coding RNAs and the epigenetics machinery: challenges and opportunities in oncology. *Epigenetics*, **2014**, 9, 75-80	5.7	28
254	Beyond miRNAs: Role of Other Noncoding RNAs in Cancer **2014**, 247-264		1
253	miR-342 regulates BRCA1 expression through modulation of ID4 in breast cancer. *PLoS ONE*, **2014**, 9, e87039	3.7	54
252	Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NF-B activation and enhances erythroid differentiation arrest. *PLoS ONE*, **2014**, 9, e93404	3.7	33
251	miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study. *PLoS ONE*, **2014**, 9, e107566	3.7	22
250	Allele frequencies of variants in ultra conserved elements identify selective pressure on transcription factor binding. *PLoS ONE*, **2014**, 9, e110692	3.7	4
249	Contact inhibition modulates intracellular levels of miR-223 in a p27kip1-dependent manner. *Oncotarget*, **2014**, 5, 1185-97	3.3	14
248	Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer. *Oncotarget*, **2014**, 5, 8492-502	3.3	15
247	NCRNA combined therapy as future treatment option for cancer. *Current Pharmaceutical Design*, **2014**, 20, 6565-74	3.3	51
246	Signal transducer and activator of transcription (STAT)-3 regulates microRNA gene expression in chronic lymphocytic leukemia cells. *Molecular Cancer*, **2013**, 12, 50	42.1	44
245	Transcription signatures encoded by ultraconserved genomic regions in human prostate cancer. *Molecular Cancer*, **2013**, 12, 13	42.1	50

244	The mix of two worlds: non-coding RNAs and hormones. *Nucleic Acid Therapeutics*, **2013**, 23, 2-8	4.8	39
243	Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. *EMBO Journal*, **2013**, 32, 2672-84	13	129
242	EGFR gets in the way of microRNA biogenesis. *Cell Research*, **2013**, 23, 1157-8	24.7	6
241	miR-124 inhibits STAT3 signaling to enhance T cell-mediated immune clearance of glioma. *Cancer Research*, **2013**, 73, 3913-26	10.1	189
240	HINCUTs in cancer: hypoxia-induced noncoding ultraconserved transcripts. *Cell Death and Differentiation*, **2013**, 20, 1675-87	12.7	85
239	A novel non-coding RNA lncRNA-JADE connects DNA damage signalling to histone H4 acetylation. *EMBO Journal*, **2013**, 32, 2833-47	13	96
238	MicroRNAs and other non-coding RNAs as targets for anticancer drug development. *Nature Reviews Drug Discovery*, **2013**, 12, 847-65	64.1	982
237	CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. *Genome Research*, **2013**, 23, 1446-61	9.7	442
236	Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. *Cancer Discovery*, **2013**, 3, 1302-15	24.4	123
235	targetHub: a programmable interface for miRNA-gene interactions. *Bioinformatics*, **2013**, 29, 2657-8	7.2	12
234	Fractal-like kinetics of intracellular enzymatic reactions: a chemical framework of endotoxin tolerance and a possible non-specific contribution of macromolecular crowding to cross-tolerance. *Theoretical Biology and Medical Modelling*, **2013**, 10, 55	2.3	9
233	Epigenetic inactivation of miR-9 family microRNAs in chronic lymphocytic leukemia--implications on constitutive activation of NFB pathway. *Molecular Cancer*, **2013**, 12, 173	42.1	60
232	Tumour angiogenesis regulation by the miR-200 family. *Nature Communications*, **2013**, 4, 2427	17.4	295
231	Bioinformatics, non-coding RNAs and its possible application in personalized medicine. *Advances in Experimental Medicine and Biology*, **2013**, 774, 21-37	3.6	8
230	Epigenetic regulation of miRNAs in cancer. *Advances in Experimental Medicine and Biology*, **2013**, 754, 137-48	3.6	70
229	miRNAs and long noncoding RNAs as biomarkers in human diseases. *Expert Review of Molecular Diagnostics*, **2013**, 13, 183-204	3.8	111
228	MicroRNA and Epigenetics: Diagnostic and Therapeutic Opportunities. *Current Pathobiology Reports*, **2013**, 1, 43-52	2	23
227	MicroRNAs and Other Non-Coding RNAs: Implications for Cancer Patients **2013**, 1-12		

226	Prooncogenic factors miR-23b and miR-27b are regulated by Her2/Neu, EGF, and TNF-□n breast cancer. *Cancer Research*, **2013**, 73, 2884-96	10.1	135
225	A miRNA signature associated with human metastatic medullary thyroid carcinoma. *Endocrine-Related Cancer*, **2013**, 20, 809-23	5.7	69
224	Wnt signaling regulates the lineage differentiation potential of mouse embryonic stem cells through Tcf3 down-regulation. *PLoS Genetics*, **2013**, 9, e1003424	6	64
223	Epigenetic silencing of microRNA-203 is required for EMT and cancer stem cell properties. *Scientific Reports*, **2013**, 3, 2687	4.9	94
222	MicroRNA analysis: is it ready for prime time?. *Clinical Chemistry*, **2013**, 59, 343-7	5.5	8
221	The MicroRNA Decalogue of Cancer Involvement **2013**, 199-221		
220	Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. *Blood*, **2013**, 122, 1891-9	2.2	157
219	MicroRNAs and cancer therapy - from bystanders to major players. *Current Medicinal Chemistry*, **2013**, 20, 3561-73	4.3	43
218	Signal transducer and activator of transcription-3 induces microRNA-155 expression in chronic lymphocytic leukemia. *PLoS ONE*, **2013**, 8, e64678	3.7	25
217	CCAT2, a novel long non-coding RNA in breast cancer: expression study and clinical correlations. *Oncotarget*, **2013**, 4, 1748-62	3.3	148
216	MicroRNAs as cancer biomarkers. *MicroRNA (Shariqah, United Arab Emirates)*, **2013**, 2, 102-17	2.9	11
215	Genome-wide and species-wide in silico screening for intragenic MicroRNAs in human, mouse and chicken. *PLoS ONE*, **2013**, 8, e65165	3.7	60
214	Expression, tissue distribution and function of miR-21 in esophageal squamous cell carcinoma. *PLoS ONE*, **2013**, 8, e73009	3.7	82
213	Coordinated targeting of the EGFR signaling axis by microRNA-27a*. *Oncotarget*, **2013**, 4, 1388-98	3.3	40
212	Functional relevance of miRNA sequences in human disease. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2012**, 731, 14-9	3.3	62
211	Small gene, big number, many effects. *Blood*, **2012**, 120, 240-1	2.2	5
210	Cell-to-cell miRNA transfer: from body homeostasis to therapy. *Pharmacology & Therapeutics*, **2012**, 136, 169-74	13.9	130
209	Strand-specific miR-28-5p and miR-28-3p have distinct effects in colorectal cancer cells. *Gastroenterology*, **2012**, 142, 886-896.e9	13.3	151

208	MiR-155 is a liposarcoma oncogene that targets casein kinase-1 and enhances -catenin signaling. *Cancer Research*, **2012**, 72, 1751-62	10.1	88
207	Novel insights of structure-based modeling for RNA-targeted drug discovery. *Journal of Chemical Information and Modeling*, **2012**, 52, 2741-53	6.1	34
206	Long non-coding RNAs and cancer: a new frontier of translational research?. *Oncogene*, **2012**, 31, 4577-87	7.2	793
205	Noncoding RNAs: Identification of Cancer-Associated MicroRNAs **2012**, 573-587		
204	Catalog of microRNA seed polymorphisms in vertebrates. *PLoS ONE*, **2012**, 7, e30737	3.7	57
203	Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer. *PLoS ONE*, **2012**, 7, e41170	3.7	54
202	Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. *Cancer*, **2012**, 118, 2603-14	6.4	220
201	Non-coding RNAs as theranostics in human cancers. *Journal of Cellular Biochemistry*, **2012**, 113, 1451-9	4.7	44
200	Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. *Clinical Cancer Research*, **2012**, 18, 3982-91	12.9	63
199	Cross talk between microRNA and coding cancer genes. *Cancer Journal (Sudbury, Mass.)*, **2012**, 18, 223-31	2.2	67
198	Decoy activity through microRNAs: the therapeutic implications. *Expert Opinion on Biological Therapy*, **2012**, 12, 1153-9	5.4	22
197	p63-microRNA feedback in keratinocyte senescence. *Proceedings of the National Academy of Sciences of the United States of America*, **2012**, 109, 1133-8	11.5	142
196	Principles of MicroRNA Involvement in Breast Cancer. *Breast Diseases*, **2011**, 22, 238-243		1
195	MicroRNAs in body fluids--the mix of hormones and biomarkers. *Nature Reviews Clinical Oncology*, **2011**, 8, 467-77	19.4	1074
194	Small molecule enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2-mediated microRNA processing. *Proceedings of the National Academy of Sciences of the United States of America*, **2011**, 108, 4394-9	11.5	183
193	OMiR: Identification of associations between OMIM diseases and microRNAs. *Genomics*, **2011**, 97, 71-6	4.3	14
192	MicroRNA regulation of ionizing radiation-induced premature senescence. *International Journal of Radiation Oncology Biology Physics*, **2011**, 81, 839-48	4	68
191	Non-coding RNAs for medical practice in oncology. *Keio Journal of Medicine*, **2011**, 60, 106-13	1.6	23

190	Circulating microRNAs let-7a and miR-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. *Blood*, **2011**, 118, 413-5	2.2	83
189	MicroRNA profiling in cancer. *Clinical Science*, **2011**, 121, 141-58	6.5	133
188	RNA interference in the clinic: challenges and future directions. *Nature Reviews Cancer*, **2011**, 11, 59-67	31.3	622
187	MicroRNA history: discovery, recent applications, and next frontiers. *Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis*, **2011**, 717, 1-8	3.3	272
186	MicroRNAs: toward the clinic for breast cancer patients. *Seminars in Oncology*, **2011**, 38, 764-75	5.5	27
185	Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA. *American Journal of Hematology*, **2011**, 86, 237-8	7.1	17
184	MicroRNA down-regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint. *Hepatology*, **2011**, 54, 2089-98	11.2	86
183	MicroRNAs miR-221 and miR-222: a new level of regulation in aggressive breast cancer. *Genome Medicine*, **2011**, 3, 56	14.4	84
182	PDGF induced microRNA alterations in cancer cells. *Nucleic Acids Research*, **2011**, 39, 4035-47	20.1	36
181	Genetic variants at the miR-124 binding site on the cytoskeleton-organizing IQGAP1 gene confer differential predisposition to breast cancer. *International Journal of Oncology*, **2011**, 38, 1153-61	4.4	23
180	Complex patterns of altered MicroRNA expression during the adenoma-adenocarcinoma sequence for microsatellite-stable colorectal cancer. *Clinical Cancer Research*, **2011**, 17, 7283-93	12.9	57
179	Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. *JAMA - Journal of the American Medical Association*, **2011**, 305, 59-67	27.4	223
178	microRNA-10b: a new marker or the marker of pancreatic ductal adenocarcinoma?. *Clinical Cancer Research*, **2011**, 17, 5527-9	12.9	16
177	Micro-RNAs in Hematologic Malignancies **2011**, 325-340		
176	Principles of microRNA involvement in human cancers. *Chinese Journal of Cancer*, **2011**, 30, 739-48		27
175	MicroRNAs in Cancer (An Overview) **2011**, 1-71		
174	Non-coding RNAs and cancer: new paradigms in oncology. *Discovery Medicine*, **2011**, 11, 245-54	2.5	34
173	CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. *Oncogene*, **2010**, 29, 6390-401	9.2	158

172	Targeting microRNAs with small molecules: from dream to reality. *Clinical Pharmacology and Therapeutics*, **2010**, 87, 754-8	6.1	119
171	miR-145 participates with TP53 in a death-promoting regulatory loop and targets estrogen receptor-alpha in human breast cancer cells. *Cell Death and Differentiation*, **2010**, 17, 246-54	12.7	205
170	miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. *Cell Death and Differentiation*, **2010**, 17, 215-20	12.7	482
169	MicroRNAs in mouse models of lymphoid malignancies. *Journal of Nucleic Acids Investigation*, **2010**, 1, 8		6
168	Role of PTPRJ genotype in papillary thyroid carcinoma risk. *Endocrine-Related Cancer*, **2010**, 17, 1001-6	5.7	24
167	Non-coding RNAs: identification of cancer-associated microRNAs by gene profiling. *Technology in Cancer Research and Treatment*, **2010**, 9, 123-38	2.7	59
166	Chemoprevention of cigarette smoke-induced alterations of MicroRNA expression in rat lungs. *Cancer Prevention Research*, **2010**, 3, 62-72	3.2	93
165	MicroRNAs: a complex regulatory network drives the acquisition of malignant cell phenotype. *Endocrine-Related Cancer*, **2010**, 17, F51-75	5.7	48
164	Non-codingRNA sequence variations in human chronic lymphocytic leukemia and colorectal cancer. *Carcinogenesis*, **2010**, 31, 208-15	4.6	65
163	MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. *Cancer Research*, **2010**, 70, 5184-93	10.1	347
162	Epigenetics and miRNAs in human cancer. *Advances in Genetics*, **2010**, 70, 87-99	3.3	140
161	GAM/ZFp/ZNF512B is central to a gene sensor circuitry involving cell-cycle regulators, TGF{beta} effectors, Drosha and microRNAs with opposite oncogenic potentials. *Nucleic Acids Research*, **2010**, 38, 7673-88	20.1	29
160	Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. *Epigenetics*, **2010**, 5, 656-63	5.7	108
159	microRNAs in cancer: from bench to bedside. *Advances in Cancer Research*, **2010**, 108, 113-57	5.9	40
158	MYC-microRNA-9-metastasis connection in breast cancer. *Cell Research*, **2010**, 20, 603-4	24.7	14
157	Non-Coding RNAs in Cancer The Other Part of the Story. *Modecular Medicine and Medicinal*, **2010**, 265-277		
156	High-throughput profiling in the hematopoietic system. *Methods in Molecular Biology*, **2010**, 667, 79-91	1.4	1
155	Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. *Cancer Research*, **2010**, 70, 2789-98	10.1	314

154	MicroRNAs, ultraconserved genes and colorectal cancers. *International Journal of Biochemistry and Cell Biology*, **2010**, 42, 1291-7	5.6	39
153	miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. *Cell*, **2010**, 140, 652-65	56.2	427
152	Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. *Lancet Oncology, The*, **2010**, 11, 136-46	21.7	671
151	MicroRNAs and metastases--the neuroblastoma link. *Cancer Biology and Therapy*, **2010**, 9, 453-4	4.6	7
150	microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival. *Blood*, **2010**, 116, 945-52	2.2	173
149	Coding and noncoding: the CLL mix. *Blood*, **2010**, 115, 3858-9	2.2	1
148	Reprogramming of miRNA networks in cancer and leukemia. *Genome Research*, **2010**, 20, 589-99	9.7	287
147	Hematopoietic differentiation: a coordinated dynamical process towards attractor stable states. *BMC Systems Biology*, **2010**, 4, 85	3.5	22
146	MicroRNAs and ultraconserved genes as diagnostic markers and therapeutic targets in cancer and cardiovascular diseases. *Journal of Cardiovascular Translational Research*, **2010**, 3, 271-9	3.3	36
145	The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade. *Cancer Microenvironment*, **2010**, 3, 137-47	6.1	81
144	Regulation of tumor angiogenesis by EZH2. *Cancer Cell*, **2010**, 18, 185-97	24.3	290
143	The Meaning of 21 in the MicroRNA world: perfection rather than destruction?. *Cancer Cell*, **2010**, 18, 203-5	24.3	11
142	A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. *Cancer Cell*, **2010**, 18, 303-15	24.3	261
141	miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma. *Genes Chromosomes and Cancer*, **2010**, 49, 981-90	5	114
140	MicroRNAs in mouse models of lymphoid malignancies. *Journal of Nucleic Acids Investigation*, **2010**, 1, 36-40		10
139	Involvement of MicroRNAs in Human Cancer: Discovery and Expression Profiling **2010**, 69-104		
138	MicroRNAs: new players in AML pathogenesis. *Cancer Treatment and Research*, **2010**, 145, 169-81	3.5	2
137	Beyond genomics: interpreting the 93% of the human genome that does not encode proteins. *Current Opinion in Drug Discovery & Development*, **2010**, 13, 350-8		8

136	MicroRNA fingerprints identify miR-150 as a plasma prognostic marker in patients with sepsis. *PLoS ONE*, **2009**, 4, e7405	3.7	236
135	Chronic lymphocytic leukemia: interplay between noncoding RNAs and protein-coding genes. *Blood* , **2009**, 114, 4761-70	2.2	81
134	Relationships of microRNA expression in mouse lung with age and exposure to cigarette smoke and light. *FASEB Journal*, **2009**, 23, 3243-50	0.9	142
133	Unique microRNA profile in end-stage heart failure indicates alterations in specific cardiovascular signaling networks. *Journal of Biological Chemistry*, **2009**, 284, 27487-99	5.4	108
132	An integrated approach for experimental target identification of hypoxia-induced miR-210. *Journal of Biological Chemistry*, **2009**, 284, 35134-43	5.4	215
131	MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. *Clinical Cancer Research*, **2009**, 15, 5073-81	12.9	267
130	MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. *Cancer Research*, **2009**, 69, 9090-5	10.1	207
129	Emerging roles of microRNAs in the molecular responses to hypoxia. *Current Pharmaceutical Design* , **2009**, 15, 3861-6	3.3	70
128	MicroRNAs and genomic variations: from Proteus tricks to Prometheus gift. *Carcinogenesis*, **2009**, 30, 912-7	4.6	26
127	An miR-502-binding site single-nucleotide polymorphism in the 3'-untranslated region of the SET8 gene is associated with early age of breast cancer onset. *Clinical Cancer Research*, **2009**, 15, 6292-300	12.9	95
126	UCbase & miRfunc: a database of ultraconserved sequences and microRNA function. *Nucleic Acids Research*, **2009**, 37, D41-8	20.1	35
125	MicroRNAs and cancer--new paradigms in molecular oncology. *Current Opinion in Cell Biology*, **2009**, 21, 470-9	9	194
124	The role of microRNA in human leukemia: a review. *Leukemia*, **2009**, 23, 1257-63	10.7	61
123	A TARBP2 mutation in human cancer impairs microRNA processing and DICER1 function. *Nature Genetics*, **2009**, 41, 365-70	36.3	317
122	MicroRNAs--the micro steering wheel of tumour metastases. *Nature Reviews Cancer*, **2009**, 9, 293-302	31.3	661
121	Downregulation of microRNA expression in the lungs of rats exposed to cigarette smoke. *FASEB Journal*, **2009**, 23, 806-12	0.9	364
120	miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. *Clinical Cancer Research*, **2009**, 15, 5060-72	12.9	353
119	MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. *Cancer Research*, **2009**, 69, 5761-7	10.1	346

118	SnapShot: MicroRNAs in Cancer. *Cell*, **2009**, 137, 586-586.e1	56.2	204
117	RNA inhibition, microRNAs, and new therapeutic agents for cancer treatment. *Clinical Lymphoma and Myeloma*, **2009**, 9 Suppl 3, S313-8		28
116	MicroRNAs in Cancer. *Annual Review of Medicine*, **2009**, 60, 167-79	17.4	1516
115	MicroRNAs in the ontogeny of leukemias and lymphomas. *Leukemia and Lymphoma*, **2009**, 50, 160-70	1.9	57
114	MicroRNAs and cancer: what we know and what we still have to learn. *Genome Medicine*, **2009**, 1, 78	14.4	17
113	MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. *Expert Opinion on Biological Therapy*, **2009**, 9, 703-711	5.4	321
112	MicroRNAs: The Jack of All Trades. *Clinical Leukemia*, **2009**, 3, 20-32		2
111	MiR-sensing chemotherapy resistance in CLL. *Blood*, **2009**, 113, 3652-3	2.2	3
110	Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. *Blood*, **2009**, 113, 3744-53	2.2	74
109	Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. *Blood*, **2009**, 113, 5568-74	2.2	112
108	miRs: fine-tuning prognosis in CLL. *Blood*, **2009**, 113, 5035-6	2.2	7
107	MicroRNA 29b functions in acute myeloid leukemia. *Blood*, **2009**, 114, 5331-41	2.2	379
106	Multiple approach to analyzing the role of microRNAs in apoptosis. *Methods in Molecular Biology*, **2009**, 559, 219-45	1.4	2
105	Significance of Aberrant Expression of MicroRNAs in Cancer Cells **2009**, 1-12		
104	MicroRNAs and Drug Resistance **2009**, 257-270		
103	MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications. *Leukemia*, **2008**, 22, 1095-105	10.7	127
102	MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. *Oncogene*, **2008**, 27, 5651-61	9.2	545
101	MicroRNA expression profiling using microarrays. *Nature Protocols*, **2008**, 3, 563-78	18.8	233

100	A microRNA component of the hypoxic response. *Cell Death and Differentiation*, **2008**, 15, 667-71	12.7	225
99	MicroRNA involvement in brain tumors: from bench to bedside. *Brain Pathology*, **2008**, 18, 122-9	6	86
98	Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. *Cancer Cell*, **2008**, 13, 496-506	24.3	423
97	MicroRNAs as new players in the genomic galaxy and disease puzzles. *Clinical and Translational Science*, **2008**, 1, 50-6	4.9	2
96	A microRNA DNA methylation signature for human cancer metastasis. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 13556-61	11.5	890
95	Mechanisms of microRNA deregulation in human cancer. *Cell Cycle*, **2008**, 7, 2643-6	4.7	263
94	MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. *JAMA - Journal of the American Medical Association*, **2008**, 299, 425-36	27.4	1233
93	ARLTS1 - a novel tumor suppressor gene. *Cancer Letters*, **2008**, 264, 11-20	9.9	16
92	MiR-15a and miR-16-1 cluster functions in human leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 5166-71	11.5	642
91	Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. *Cancer Research*, **2008**, 68, 6162-70	10.1	600
90	MicroRNAs as new biomarkers in oncology. *Expert Opinion on Medical Diagnostics*, **2008**, 2, 115-27		3
89	In silico prediction of target SNPs affecting miR-mRNA interaction **2008**,		1
88	MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. *Cancer Research*, **2008**, 68, 10307-14	10.1	302
87	Polymorphisms in microRNA targets: a gold mine for molecular epidemiology. *Carcinogenesis*, **2008**, 29, 1306-11	4.6	213
86	Potential therapeutic applications of miRNA-based technology in hematological malignancies. *Current Pharmaceutical Design*, **2008**, 14, 2040-50	3.3	20
85	Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2008**, 105, 7004-9	11.5	443
84	MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. *Blood*, **2008**, 111, 3183-9	2.2	536
83	MicroRNAs. *Cancer Journal (Sudbury, Mass)*, **2008**, 14, 1-6	2.2	158

82	Expression and function of micro-RNAs in immune cells during normal or disease state. *International Journal of Medical Sciences*, **2008**, 5, 73-9	3.7	78
81	MicroRNAs and cancer: profile, profile, profile. *International Journal of Cancer*, **2008**, 122, 969-77	7.5	157
80	Cancer-associated genomic regions (CAGRs) and noncoding RNAs: bioinformatics and therapeutic implications. *Mammalian Genome*, **2008**, 19, 526-40	3.2	59
79	Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. *Prostate*, **2008**, 68, 1152-64	4.2	127
78	Molecular Pathogenesis **2008**, 35-44		
77	mRNA/microRNA gene expression profile in microsatellite unstable colorectal cancer. *Molecular Cancer*, **2007**, 6, 54	42.1	215
76	The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. *Best Practice and Research in Clinical Haematology*, **2007**, 20, 425-37	4.2	79
75	A microRNA signature of hypoxia. *Molecular and Cellular Biology*, **2007**, 27, 1859-67	4.8	881
74	Identification of differentially expressed microRNAs by microarray: a possible role for microRNA genes in pituitary adenomas. *Journal of Cellular Physiology*, **2007**, 210, 370-7	7	183
73	Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. *Oncogene*, **2007**, 26, 7590-5	9.2	342
72	Chronic lymphocytic leukaemia genetics overview. *British Journal of Haematology*, **2007**, 139, 630-4	4.5	22
71	MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. *British Journal of Haematology*, **2007**, 139, 709-16	4.5	50
70	Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. *Cancer Cell*, **2007**, 12, 215-29	24.3	599
69	MicroRNA genes are frequently located near mouse cancer susceptibility loci. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 8017-22	11.5	131
68	Regulation of microRNA Expression: the Hypoxic Component. *Cell Cycle*, **2007**, 6, 1425-1430	4.7	103
67	Regulatory mechanisms of microRNAs involvement in cancer. *Expert Opinion on Biological Therapy*, **2007**, 7, 1009-19	5.4	135
66	CD34+ hematopoietic stem-progenitor cell microRNA expression and function: a circuit diagram of differentiation control. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 2750-5	11.5	424
65	ARLTS1 Trp149Stop Mutation and the Risk of Ovarian Cancer. *Cancer Research*, **2007**, 67, 4534-4534	10.1	

64	Tumor suppressor functions of ARLTS1 in lung cancers. *Cancer Research*, **2007**, 67, 7738-45	10.1	13
63	Micro-RNA profiling in kidney and bladder cancers. *Urologic Oncology: Seminars and Original Investigations*, **2007**, 25, 387-92	2.8	522
62	MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. *Oncogene*, **2007**, 26, 4148-57	9.2	322
61	Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. *Cancer Research*, **2007**, 67, 6092-9	10.1	695
60	MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 15805-10	11.5	1385
59	Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. *Journal of Immunology*, **2007**, 179, 5082-9	5.3	1091
58	MicroRNA signatures in human ovarian cancer. *Cancer Research*, **2007**, 67, 8699-707	10.1	1251
57	Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. *Journal of Clinical Investigation*, **2007**, 117, 2059-66	15.9	131
56	Regulation of microRNA expression: the hypoxic component. *Cell Cycle*, **2007**, 6, 1426-31	4.7	72
55	Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. *Cancer Cell*, **2006**, 9, 189-98	24.3	2606
54	Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. *Seminars in Oncology*, **2006**, 33, 167-73	5.5	122
53	MicroRNAs: fundamental facts and involvement in human diseases. *Birth Defects Research Part C: Embryo Today Reviews*, **2006**, 78, 180-9		70
52	Expression profiles of micro RNA in proliferating and differentiating 32D murine myeloid cells. *Journal of Cellular Physiology*, **2006**, 207, 706-10	7	13
51	MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. *Journal of Clinical Oncology*, **2006**, 24, 4677-84	2.2	658
50	MicroRNA fingerprints during human megakaryocytopoiesis. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 5078-83	11.5	386
49	Effect of rapamycin on mouse chronic lymphocytic leukemia and the development of nonhematopoietic malignancies in Emu-TCL1 transgenic mice. *Cancer Research*, **2006**, 66, 915-20	10.1	66
48	Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. *Cancer Research*, **2006**, 66, 10287-91	10.1	44
47	A microRNA expression signature of human solid tumors defines cancer gene targets. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 2257-61	11.5	4710

46	Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. *Cancer Research*, **2006**, 66, 11590-3	10.1	528
45	MicroRNA-cancer connection: the beginning of a new tale. *Cancer Research*, **2006**, 66, 7390-4	10.1	874
44	MicroRNA expression and function in cancer. *Trends in Molecular Medicine*, **2006**, 12, 580-7	11.5	615
43	MicroRNA signatures in human cancers. *Nature Reviews Cancer*, **2006**, 6, 857-66	31.3	6256
42	MicroRNAs and chromosomal abnormalities in cancer cells. *Oncogene*, **2006**, 25, 6202-10	9.2	218
41	Mammalian microRNAs: a small world for fine-tuning gene expression. *Mammalian Genome*, **2006**, 17, 189-202	3.2	275
40	MicroRNA Expression and Regulation of Hematopoiesis in CD34+ Cells: A Bioinformatic Circuit Diagram of the Hematopoietic Differentiation Control.. *Blood*, **2006**, 108, 1334-1334	2.2	
39	miRNAs, cancer, and stem cell division. *Cell*, **2005**, 122, 6-7	56.2	1156
38	Cloning and characterization of cDNAs expressed during chick development and encoding different isoforms of a putative zinc finger transcriptional regulator. *Biochimie*, **2005**, 87, 939-49	4.6	5
37	MicroRNA gene expression deregulation in human breast cancer. *Cancer Research*, **2005**, 65, 7065-70	10.1	3315
36	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. *New England Journal of Medicine*, **2005**, 353, 1793-801	59.2	2041
35	Familial cancer associated with a polymorphism in ARLTS1. *New England Journal of Medicine*, **2005**, 352, 1667-76	59.2	101
34	Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency. *Cancer Research*, **2005**, 65, 6576-82	10.1	29
33	miR-15 and miR-16 induce apoptosis by targeting BCL2. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 13944-9	11.5	2912
32	The role of microRNA genes in papillary thyroid carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 19075-80	11.5	1025
31	MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation. *Proceedings of the National Academy of Sciences of the United States of America*, **2005**, 102, 18081-6	11.5	691
30	Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. *Clinical Cancer Research*, **2004**, 10, 2720-4	12.9	98
29	Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. *Cancer Research*, **2004**, 64, 8156-9	10.1	89

28	Role of pescadillo and upstream binding factor in the proliferation and differentiation of murine myeloid cells. *Molecular and Cellular Biology*, **2004**, 24, 5421-33	4.8	29
27	An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 9740-4	11.5	831
26	MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 11755-60	11.5	1103
25	Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 2999-3004	11.5	3326
24	Genetic chaos and antichaos in human cancers. *Medical Hypotheses*, **2003**, 60, 258-62	3.8	20
23	Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. *Proceedings of the National Academy of Sciences of the United States of America*, **2003**, 100, 5956-61	11.5	246
22	Regulation of BRCA1 transcription by specific single-stranded DNA binding factors. *Molecular and Cellular Biology*, **2003**, 23, 3774-87	4.8	52
21	Multigene Methylation Analysis of Gastrointestinal Tumors. *Molecular Diagnosis and Therapy*, **2003**, 7, 201-207		32
20	Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 15524-9	11.5	4014
19	Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 6955-60	11.5	469
18	Loss of methylation at chromosome 11p15.5 is common in human adult tumors. *Oncogene*, **2002**, 21, 2564-72	9.2	49
17	Somatic frameshift mutations in the Bloom syndrome BLM gene are frequent in sporadic gastric carcinomas with microsatellite mutator phenotype. *BMC Genetics*, **2001**, 2, 14	2.6	13
16	Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. *International Journal of Cancer*, **2000**, 89, 230-235	7.5	91
15	FAP and marfanoid habitus. *European Journal of Human Genetics*, **2000**, 8, 153	5.3	
14	Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. *Oncogene*, **2000**, 19, 1191-5	9.2	187
13	Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. *Proceedings of the National Academy of Sciences of the United States of America*, **2000**, 97, 5445-9	11.5	74
12	Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: A study of the TGRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes **2000**, 89, 230		4
11	Marfan-like habitus and familial adenomatous polyposis in two unrelated males: a significant association?. *European Journal of Human Genetics*, **1999**, 7, 609-14	5.3	2

10	Refinement of the LOH region 1 at 11q23.1 deleted in human breast carcinomas and sublocalization of 11 expressed sequence tags within the refined region. *Oncogene*, **1999**, 18, 1635-8	9.2	24
9	The difference between p53 mutation frequency in haematological and non-haematological malignancies: possible explanations. *Medical Hypotheses*, **1999**, 53, 326-8	3.8	3
8	t(1;7)(p36;q32): a new recurring abnormality in primary myelodysplastic syndrome. *Cancer Genetics and Cytogenetics*, **1994**, 75, 103-5		5
7	A complex translocation t(1-12-11) in a patient with hodgkins-disease. *Oncology Reports*, **1994**, 1, 837-9	3.5	
6	Oncogenes and tumor-suppressor genes - 2 different looks of the same gene. *Oncology Reports*, **1994**, 1, 987-91	3.5	4
5	T-cell malignant lymphoma with a complex unbalanced translocation (8;11;14). *Cancer Genetics and Cytogenetics*, **1993**, 70, 71-3		
4	Small silencing non-coding RNAs: cancer connections and significance481-496		
3	MicroRNAs in Cancer1-16		1
2	MicroRNAs as Drugs and Drug Targets in Cancer97-111		
1	MicroRNAs in Cancer		1